<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction

descriptionPublicationkeyboard_double_arrow_right Part of book or chapter of book , Article 01 Jan 2016 Italy Publisher:Springer International Publishing

Authors: Senni M.; D'Elia E.; Emdin M.; Vergaro G.;

doi: 10.1007/164_2016_86

pmid: 28181009

handle: 11382/537524

Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction

- Summary
- Subjects
- Metrics

Abstract

Biomarkers are increaingly being used in the management of heart failure not only for the purpose of screening, diagnosis, and risk stratification, but also as a guide to evaluate the response to treatment in the individual patient and as an entry criterion and/or a surrogate marker of efficacy in clinical trials testing novel drugs. In this chapter, we review the role of established biomarkers for heart failure management, according to the main classification of HF phenotypes, based on the measurement of left ventricular ejection fraction, including heart failure with reduced (<40%), preserved (≥50%), and, as recently proposed, mid-range (40-49%) ejection fraction.

Country

Italy

Related Organizations

Sant'Anna School of Advanced Studies
Italy
Ospedale Papa Giovanni XXIII
Italy
Life Science Institute
Japan

Keywords

Heart Failure, Growth Differentiation Factor 15, Cardio-Renal Syndrome, Interleukin-6, Angiotensin II, Galectin 3, Glycopeptides, Interleukin-18, Interleukin-1 Receptor-Like 1 Protein, Adrenomedullin, C-Reactive Protein, Catecholamines, Biomarkers; Diagnosis; Heart failure management; Prognosis; Screening; Adrenomedullin; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Biomarkers; C-Reactive Protein; Cardio-Renal Syndrome; Catecholamines; Chromogranin A; Creatinine; Galectin 3; Glycopeptides; Growth Differentiation Factor 15; Heart Failure; Hepatitis A Virus Cellular Receptor 1; Humans; Interleukin-1; Interleukin-1 Receptor-Like 1 Protein; Interleukin-18; Interleukin-6; Lipocalin-2; MicroRNAs; Natriuretic Peptide, Brain; Peptide Fragments; Renin; Renin-Angiotensin System; Troponin; Troponin T; Tumor Necrosis Factor-alpha; beta-N-Acetyl-Galactosaminidase; Stroke Volume, Creatinine, Chromogranin A, Humans, Hepatitis A Virus Cellular Receptor 1, Aldosterone, Atrial Natriuretic Factor, Biomarkers, Interleukin-1

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	10
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average